Literature DB >> 9536262

Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.

S Finke1, B Trojaneck, P Lefterova, M Csipai, E Wagner, R Kircheis, A Neubauer, D Huhn, B Wittig, I G Schmidt-Wolf.   

Abstract

Cytokine-induced killer (CIK) cells have been shown to eradicate established tumors in a SCID mouse-human lymphoma model. CIK cells depend on exogenous addition of cytokines such as interleukin-2 (IL-2), interleukin-7 (IL-7) or interleukin-12 (IL-12) for proliferation. In this study, we used the adenovirus-enhanced CD3 receptor-mediated gene transfer for transfection with the IL-7 gene. An episomally replicating plasmid was used containing cDNA of the human IL-7 gene under the control of a CMV promoter for transfection of CIK cells. Biosynthesis of IL-7 was demonstrated by RT-PCR, an enzyme-linked immunosorbent assay (ELISA) and using a bioassay. Transfected cells produced IL-7 in the range between 200 and 1100 pg/10(6) cells in 24 h. IL-7 was shown to be biologically active, since transfected CIK cells showed an improved proliferation rate as compared with nontransfected cells. Expression of IL-7 altered the secretion of other cytokines by CIK cells, in particular the production of TNF alpha increased after transfection. In contrast, nontransfected CIK cells fed with IL-7 showed no increase in TNF alpha secretion. No significant differences were found in expression of surface antigens linked to the cytotoxic activity of CIK cells. Cytotoxic activity against various tumor cell lines (eg renal cell carcinoma, malignant melanoma and colon carcinoma) was tested. Transfected cells possessed a significantly higher cytotoxic activity as compared with nontransfected cells. Receptor-mediated gene transfer effectively delivers expression plasmids for therapeutic genes into CIK cells and CIK cells transfected with an IL-7 gene expression construct may be valuable for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536262     DOI: 10.1038/sj.gt.3300560

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  12 in total

1.  Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.

Authors:  Fu-Sheng Wang; Ming-Xu Liu; Bing Zhang; Ming Shi; Zhou-Yun Lei; Wen-Bing Sun; Qing-You Du; Ju-Mei Chen
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

2.  Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.

Authors:  Zhi Yang; Qianzhen Zhang; Ke Xu; Juanjuan Shan; Junjie Shen; Limei Liu; Yanmin Xu; Feng Xia; Ping Bie; Xia Zhang; Youhong Cui; Xiu-Wu Bian; Cheng Qian
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 3.  Cancer Immunotherapy with Cytokine-Induced Killer Cells.

Authors:  Juan J Mata-Molanes; Manuel Sureda González; Belén Valenzuela Jiménez; Elena Mª Martínez Navarro; Antonio Brugarolas Masllorens
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.864

4.  CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.

Authors:  Xin-Rui Lin; Xin-Liang Zhou; Qiang Feng; Xin-Yan Pan; Shu-Ling Song; Hong Fang; Jin Lei; Ju-Lun Yang
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-22       Impact factor: 4.322

5.  Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.

Authors:  I G Schmidt-Wolf; S Finke; B Trojaneck; A Denkena; P Lefterova; N Schwella; H G Heuft; G Prange; M Korte; M Takeya; T Dorbic; A Neubauer; B Wittig; D Huhn
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

Review 6.  Cytokine-induced killer (CIK) cells: from basic research to clinical translation.

Authors:  Yelei Guo; Weidong Han
Journal:  Chin J Cancer       Date:  2015-03-05

7.  Novel non-viral method for transfection of primary leukemia cells and cell lines.

Authors:  Frank Schakowski; Peter Buttgereit; Martin Mazur; Angela Märten; Björn Schöttker; Marcus Gorschlüter; Ingo GH Schmidt-Wolf
Journal:  Genet Vaccines Ther       Date:  2004-01-12

8.  Targeting regulatory T cells in cytokine-induced killer cell cultures (Review).

Authors:  Qianshan Tao; Huiping Wang; Zhimin Zhai
Journal:  Biomed Rep       Date:  2014-02-07

9.  IL-7 receptor recovery on CD8 T-cells isolated from HIV+ patients is inhibited by the HIV Tat protein.

Authors:  Elliott M Faller; Mark J McVey; Paul A MacPherson
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

Review 10.  Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.

Authors:  Frederic Carsten Schmeel; Leonard Christopher Schmeel; Sanna-Marie Gast; Ingo G H Schmidt-Wolf
Journal:  Int J Mol Sci       Date:  2014-08-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.